Document is current

Any future updates will be listed below

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab

Crossref DOI link: https://doi.org/10.1186/s40880-016-0166-3

Published Online: 2016-12-22

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark